Filtered By:
Cancer: Lymphoma
This page shows you your search results in order of date. This is page number 17.
Order by Relevance | Date
Total 25227 results found since Jan 2013.
Lisocabtagene maraleucel CAR-T cells - second line treatment in patients with relapsed or refractory large B cell lymphoma
Bull Cancer. 2023 Sep 1:S0007-4551(23)00334-X. doi: 10.1016/j.bulcan.2023.06.010. Online ahead of print.NO ABSTRACTPMID:37661551 | DOI:10.1016/j.bulcan.2023.06.010
Source: Bulletin du Cancer - September 4, 2023 Category: Cancer & Oncology Authors: Mathilde Chanut Charles Herbaux Source Type: research
Retrospective Case-Control Study of REGEN-COV (casirivimab and imdevimab) Therapy for Patients with COVID-19 and Cancer Using the United States MarketScan ® Database
Conclusion Patients with cancer treated with REGEN-COV experienced a decreased risk for hospitalization, hospitalization duration, and total COVID-19-related costs. Patients with cancer were at a higher risk of being hospitalized for COVID-19 than were those without cancer. The use of neutralizing antibody therapy may reduce the risk of severe COVID-19 infection for patients with cancer with an otherwise high risk. Future replication studies should be conducted using other databases that include Medicaid users and other insured persons for comparison and validation.PMID:37666220 | DOI:10.1159/000533614
Source: Oncology - September 4, 2023 Category: Cancer & Oncology Authors: Kazue Takemoto Source Type: research
SOHO State of the Art Updates and Next Questions | Immunotherapeutic Options for Patients With Mantle Cell Lymphoma Who Progress on BTK Inhibitors
Clin Lymphoma Myeloma Leuk. 2023 Aug 14:S2152-2650(23)00258-6. doi: 10.1016/j.clml.2023.08.011. Online ahead of print.ABSTRACTMantle cell lymphoma is a challenging subtype of B-cell non-Hodgkin lymphoma treat characterized by its aggressive nature and propensity for relapse or refractory (R/R) disease for many patients. The introduction of Bruton's tyrosine kinase inhibitors has significantly improved the outcomes for patients with R/R MCL, but a considerable proportion of patients eventually experience disease progression or develop resistance to these agents. In recent years, immunotherapeutic approaches have emerged as ...
Source: Clinical Lymphoma and Myeloma - September 4, 2023 Category: Cancer & Oncology Authors: Rahul K Nayak Drew Gerber Chen Zhang Jonathon B Cohen Source Type: research
Sotorasib after immune checkpoint inhibitor administration induces hepatotoxicity. True, false or just another adverse effect of NSCLC treatment
Cancer Treat Res Commun. 2023 Aug 31:100757. doi: 10.1016/j.ctarc.2023.100757. Online ahead of print.ABSTRACTNon-small cell lung cancer is still diagnosed at a late disease stage and systematic therapy is necessary. Currently we have three main treatment modalities; chemotherapy, targeted with tyrosine kinase inhibitors and immune check point inhibitors. In the recent years and based on new studies we can administer combination of chemotherapy and immunotherapy, or radiotherapy and immunotherapy. Every treatment approach is based on the specific gene expression of the tumor. Tyrosine kinase inhibitors have been used for mo...
Source: Cell Research - September 4, 2023 Category: Cytology Authors: Paul Zarogoulidis Dimitris Matthaios Panagoula Oikonomou Christina Nikolaou Charalampos Charalampidis Chrysanthi Sardeli Source Type: research
Ultrasonographic findings of multicentric malignant lymphoma involving the urinary bladder in a dog: Diagnosis and monitoring during chemotherapy
Can Vet J. 2023 Sep;64(9):844-848.ABSTRACTA 5.5-year-old spayed female cane corso dog was presented for recurrent hematuria and dysuria. Abdominal ultrasound demonstrated severe hypoechoic urinary bladder wall thickening with irregular mucosal surface and polypoid-like lesions protruding into the lumen, abdominal polyadenomegaly, and splenic honeycombing. High-grade lymphoma was diagnosed on urinary bladder wall cytology. Clinical signs and ultrasonographic findings initially improved following a modified CHOP-based chemotherapy protocol, but the multicentric lymphoma then progressed with thoracic spread, leading to the do...
Source: The Canadian Veterinary Journal - September 4, 2023 Category: Veterinary Research Authors: Antonin Martenne-Duplan Cindy Chervier Marl ène Finck Source Type: research
Correction: Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes
Leukemia. 2023 Sep 4. doi: 10.1038/s41375-023-01978-x. Online ahead of print.NO ABSTRACTPMID:37666943 | DOI:10.1038/s41375-023-01978-x
Source: Cancer Control - September 4, 2023 Category: Cancer & Oncology Authors: Sonja I Berndt Joseph Vijai Yolanda Benavente Nicola J Camp Alexandra Nieters Zhaoming Wang Karin E Smedby Geffen Kleinstern Henrik Hjalgrim Caroline Besson Christine F Skibola Lindsay M Morton Angela R Brooks-Wilson Lauren R Teras Charles Breeze Joshua A Source Type: research
Retrospective Case-Control Study of REGEN-COV (casirivimab and imdevimab) Therapy for Patients with COVID-19 and Cancer Using the United States MarketScan ® Database
Conclusion Patients with cancer treated with REGEN-COV experienced a decreased risk for hospitalization, hospitalization duration, and total COVID-19-related costs. Patients with cancer were at a higher risk of being hospitalized for COVID-19 than were those without cancer. The use of neutralizing antibody therapy may reduce the risk of severe COVID-19 infection for patients with cancer with an otherwise high risk. Future replication studies should be conducted using other databases that include Medicaid users and other insured persons for comparison and validation.PMID:37666220 | DOI:10.1159/000533614
Source: Oncology - September 4, 2023 Category: Cancer & Oncology Authors: Kazue Takemoto Source Type: research
SOHO State of the Art Updates and Next Questions | Immunotherapeutic Options for Patients With Mantle Cell Lymphoma Who Progress on BTK Inhibitors
Clin Lymphoma Myeloma Leuk. 2023 Aug 14:S2152-2650(23)00258-6. doi: 10.1016/j.clml.2023.08.011. Online ahead of print.ABSTRACTMantle cell lymphoma is a challenging subtype of B-cell non-Hodgkin lymphoma treat characterized by its aggressive nature and propensity for relapse or refractory (R/R) disease for many patients. The introduction of Bruton's tyrosine kinase inhibitors has significantly improved the outcomes for patients with R/R MCL, but a considerable proportion of patients eventually experience disease progression or develop resistance to these agents. In recent years, immunotherapeutic approaches have emerged as ...
Source: Clinical Lymphoma and Myeloma - September 4, 2023 Category: Cancer & Oncology Authors: Rahul K Nayak Drew Gerber Chen Zhang Jonathon B Cohen Source Type: research
Lisocabtagene maraleucel CAR-T cells - second line treatment in patients with relapsed or refractory large B cell lymphoma
Bull Cancer. 2023 Sep 1:S0007-4551(23)00334-X. doi: 10.1016/j.bulcan.2023.06.010. Online ahead of print.NO ABSTRACTPMID:37661551 | DOI:10.1016/j.bulcan.2023.06.010
Source: Bulletin du Cancer - September 4, 2023 Category: Cancer & Oncology Authors: Mathilde Chanut Charles Herbaux Source Type: research
A pathogenic germline BRCA1 mutation identified in a patient with non-Hodgkin lymphoma and rectum adenocarcinoma: "Non-classical" hereditary cancer?
Asian J Surg. 2023 Sep 1:S1015-9584(23)01302-7. doi: 10.1016/j.asjsur.2023.08.134. Online ahead of print.NO ABSTRACTPMID:37661479 | DOI:10.1016/j.asjsur.2023.08.134
Source: Asian Journal of Surgery - September 4, 2023 Category: Surgery Authors: You Zhou Yanjie Xu Jiemin Zhao Wenwei Hu Source Type: research
Ultrasonographic findings of multicentric malignant lymphoma involving the urinary bladder in a dog: Diagnosis and monitoring during chemotherapy
Can Vet J. 2023 Sep;64(9):844-848.ABSTRACTA 5.5-year-old spayed female cane corso dog was presented for recurrent hematuria and dysuria. Abdominal ultrasound demonstrated severe hypoechoic urinary bladder wall thickening with irregular mucosal surface and polypoid-like lesions protruding into the lumen, abdominal polyadenomegaly, and splenic honeycombing. High-grade lymphoma was diagnosed on urinary bladder wall cytology. Clinical signs and ultrasonographic findings initially improved following a modified CHOP-based chemotherapy protocol, but the multicentric lymphoma then progressed with thoracic spread, leading to the do...
Source: The Canadian Veterinary Journal - September 4, 2023 Category: Veterinary Research Authors: Antonin Martenne-Duplan Cindy Chervier Marl ène Finck Source Type: research
Lisocabtagene maraleucel CAR-T cells - second line treatment in patients with relapsed or refractory large B cell lymphoma
Bull Cancer. 2023 Sep 1:S0007-4551(23)00334-X. doi: 10.1016/j.bulcan.2023.06.010. Online ahead of print.NO ABSTRACTPMID:37661551 | DOI:10.1016/j.bulcan.2023.06.010
Source: Bulletin du Cancer - September 4, 2023 Category: Cancer & Oncology Authors: Mathilde Chanut Charles Herbaux Source Type: research
CDK9 Inhibitor Induces Apoptosis, Autophagy, and Suppression of Tumor Growth in Adult T-Cell Leukemia/Lymphoma
Biol Pharm Bull. 2023;46(9):1269-1276. doi: 10.1248/bpb.b23-00228.ABSTRACTAdult T-cell leukemia/lymphoma (ATL) is a hematopoietic malignancy with a poor prognosis that develops in approximately 5% of human T-cell leukemia virus type 1 (HTLV-1) carriers. Cyclin-dependent kinase 9 (CDK9), together with Cyclin T, forms a transcription elongation factor, positive transcription elongation factor b (P-TEFb). P-TEFb promotes transcriptional elongation by phosphorylating the second serine (Ser2) of the seven amino acid repeat sequence in the C-terminal domain of RNA polymerase II (RNAP II). CDK9 inhibitors suppress cell proliferat...
Source: Biological and Pharmaceutical Bulletin - September 4, 2023 Category: Drugs & Pharmacology Authors: Naho Kato Tomohiro Kozako Takeo Ohsugi Yuichiro Uchida Makoto Yoshimitsu Kenji Ishitsuka Akiyoshi Aikawa Shin-Ichiro Honda Source Type: research
